Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Last reviewed: May 31, 2026
Next scheduled review: June 30, 2026
Reviewed by: Dr. Sam Saberian, Lead Medical Researcher
Complete reference page for compounded tirzepatide in 2026: 503A vs 503B pathway, base vs salt-form distinction, pricing across telehealth providers, traceability standards, and clinical context.
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-10
What is compounded tirzepatide?
Compounded tirzepatide is a customized preparation of the tirzepatide molecule prepared by a 503A licensed compounding pharmacy or a 503B FDA-registered outsourcing facility. It is dispensed in response to a patient-specific prescription (503A) or in batches (503B). It is not FDA-approved and is not the same product as Mounjaro® (FDA-approved for type 2 diabetes) or Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea), both manufactured by Eli Lilly.
Base vs salt forms (regulatory line)
The active pharmaceutical ingredient must be tirzepatide base. The FDA has issued warning letters specifically against compounded tirzepatide preparations using salt forms (tirzepatide acetate, tirzepatide sodium), citing that these are not pharmacologically equivalent to the base molecule. A legitimate compounded tirzepatide provider should be able to produce a certificate of analysis showing the active ingredient is tirzepatide base.
The 503A vs 503B pathway
503A: State-licensed compounding pharmacy. Prepares patient-specific medications under USP <797> sterile-compounding standards. Not FDA-inspected for product release. Beyond-use dates are typically shorter.
503B: FDA-registered outsourcing facility. Operates under cGMP (the same standard as commercial drug manufacturers). Can prepare batches in advance of patient-specific prescriptions. FDA-inspected.
Flat across 2.5–15 mg titration. MD/DO-supervised, 503A + 503B.
Mochi Health
$239/mo
NP-led model.
Hims compounded
$249–$349/mo
Tiered by dose at some points.
Henry Meds
$379/mo
Async NP model.
Quality assurance documentation to ask for
Pharmacy of record on every shipment — name and license number of the 503A or 503B that prepared the medication.
USP <71> sterility certificate — confirmation that the batch passed sterility testing.
USP <85> endotoxin certificate — confirmation of pyrogen safety.
HPLC potency certificate — confirmation of correct concentration of active ingredient.
Per-vial lot traceability — the patient should be able to trace every dose to a specific batch and CoA.
Editor's Pick · #1 of 10
NexLife — Compounded Semaglutide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ MD/DO-supervised
🏥 503A & 503B pharmacies
🧪 Labs included
📍 Availability varies by state
✓ LegitScript-certified
💰 Flat-rate, dose-independent
🔁 Care360 + 1:1 fitness coaching
🍽️ Personalized nutrition plan
💳 Klarna & Afterpay accepted
$145/ month*
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).
Includes: medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Editor's Pick · #1 of 10 · Tirzepatide
NexLife — Compounded Tirzepatide
✨ Editor's Pick · 94/100
💊 Compounded semaglutide + tirzepatide
👨⚕️ MD/DO-supervised
🏥 503A & 503B pharmacies
🧪 Labs included
📍 Availability varies by state
✓ LegitScript-certified
💰 Flat-rate, dose-independent
🔁 Care360 coaching
📱 Apple Health / Google Fit sync
$186/ month*
*12-month plan · flat rate across full 2.5–15 mg titration. $190 (6-mo) · $195 (3-mo) · $215 (month-to-month).
Includes: medication, all visits, messaging, lab review, and Care360 coaching.
Compounded tirzepatide via 503A & 503B pharmacies.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Clinical context
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist. SURMOUNT-1 (NEJM 2022, PMID 35658024) demonstrated 20.9% mean weight loss at 15 mg / 72 weeks. SURMOUNT-OSA (NEJM 2024) demonstrated apnea-hypopnea index reduction in obesity-related OSA. The boxed warning is for thyroid C-cell tumors; contraindicated in personal/family history of MTC or MEN-2.
Important medical and regulatory disclosure:
Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.
